EFTA01177305Set 9
3p1,238w
T790M within the EGFR kinase domain.
PED's work caught the attention ofDr. Bert Vogelstein, the Director of the Ludwig Center for Cancer Genetics and
Therapeutics at the Sidney Kimmel ... Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help,
EFTA01177305
Vogelstein ... year to predominance and tumor
level. Based on these findings, amongst others, Dr. Vogelstein and Dr. Nowak concluded that a cocktail of inhibitor
drugs and in the right proportion, must
https://www.justice.gov/epstein/files/DataSet%209/EFTA01177305.pdf
EFTA00760692Set 9
302p12,726w
evolution. P Natl Acad Sci USA 100: 14966-14969.
Rajagopalan H, MA Nowak, B Vogelstein, C Lengauer (2003). The significance
of unstable chromosomes in colorectal cancer. Nat Rev Cancer ... cancer. Semin Cancer Biol 15: 484-493.
Michor F, Y Iwasa, C Lengauer, B Vogelstein, MA Nowak (2005). Can
chromosomal instability initiate tumorigenesis? Semin Cancer Biol 15: 43-
49.
Michor ... Beerenwinkel N, T Antal, D Dingli, A Traulsen, KW Kinzler, VE Velculescu,
B Vogelstein, MA Nowak (2007). Genetic progression and the waiting time to
cancer. PLoS Comput Biol 3: e225
https://www.justice.gov/epstein/files/DataSet%209/EFTA00760692.pdf
T790M within the EGER kinase domain.
PED's work caught the attention ofIle. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney
Kimmel ... Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer
inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein ... year to predominance and tumor level. Based on these findings, amongst others, Dr. Vogelstein and II,.
Nowak concluded that a cocktail of inhibitor drugs and in the right proportion. must
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01935187.pdf
T790M within the EGER kinase domain.
PED's work caught the attention ofIle. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney
Kimmel ... Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer
inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein ... year to predominance and tumor level. Based on these findings, amongst others, Dr. Vogelstein and II,.
Nowak concluded that a cocktail of inhibitor drugs and in the right proportion. must
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01937772.pdf
EFTA00583237Set 9
3p1,238w
T790M within the EGFR kinase domain.
PED's work caught the attention ofDr. Bert Vogelstein, the Director of the Ludwig Center for Cancer Genetics and
Therapeutics at the Sidney Kimmel ... Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help,
EFTA00583237
Vogelstein ... year to predominance and tumor
level. Based on these findings, amongst others, Dr. Vogelstein and Dr. Nowak concluded that a cocktail of inhibitor
drugs and in the right proportion, must
https://www.justice.gov/epstein/files/DataSet%209/EFTA00583237.pdf
EFTA02443859Set 11
12p5,813w
Nail
Acad Sci USA 100: 14966-14969.
15. Rajagopalan H, MA Nowak, B Vogelstein, C Lengauer (2003). The significance of unstable
chromosomes in colorectal cancer. Nat Rev Cancer ... Semin
Cancer Biol 15: 484-493.
85. Michor F, Y Iwasa, C Lengauer, B Vogelstein, MA Nowak (2005). Can chromosomal
instability initiate tumorigenesis? Semin Cancer Biol ... Beerenwinkel N, T Antal, D Dingli, A Traulsen, KW Kinzler, VE Velculescu, B Vogelstein,
MA Nowak (2007). Genetic progression and the waiting time to cancer. PLoS Comput Biol
3: e225
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02443859.pdf
cancer almost always returns, and is usually
more resilient and faster growing.
Dr. Bert Vogelstein at John Hopkins, who instigated the investigation of the 28 colon cancer patients,
enlisted ... first one," Martin Nowak asserted to the New York
Times.
Based on this, Dr. Vogelstein and Dr. Nowak concluded that a cocktail of inhibitor drugs must be used to
target
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01937686.pdf
EFTA00760684Set 9
8p2,536w
Driver and passenger mutations in cancer progression — Ivan Bozic, Tibor Antal, Martin Nowak, Bert Vogelstein
Indirect Speech — Martin Nowak [with Steven Pinker (Psychology)]
Facilitated Evolution — Martin Nowak [with Marc Kirschner ... Tibor Antal and
Ivana Bozic [with Hisashi Ohtsuki (Tokyo Institute of Technology) and Bert Vogelstein [Johns Hopkins
University])
A Theoretical Investigation of the Role of Costly Punishment in the Repeated
https://www.justice.gov/epstein/files/DataSet%209/EFTA00760684.pdf
EFTA00982049Set 9
2014-01-302p437w
cancer almost always returns, and is
usually more resilient and faster growing.
Dr. Bert Vogelstein at Johns Hopkins, who
instigated the investigation of the 28 colon
cancer patients, enlisted ... first one," Martin Nowak asserted to the
New York Times.
Based on this, Dr. Vogelstein and Dr. Nowak
concluded that a cocktail of inhibitor drugs
must be used to target
https://www.justice.gov/epstein/files/DataSet%209/EFTA00982049.pdf
cancer almost always returns, and is usually
more resilient and faster growing.
Dr. Bert Vogelstein at John Hopkins, who instigated the investigation of the 28 colon cancer patients,
enlisted ... first one," Martin Nowak asserted to the New York
Times.
Based on this, Dr. Vogelstein and Dr. Nowak concluded that a cocktail of inhibitor drugs must be used to
target
https://www.justice.gov/epstein/files/DataSet%209/EFTA01149566.pdf
EFTA00603737Set 9
17p11,455w
limit intratumour heterogeneity
Bartlomiej WaclawI, Ivana Bozic13, Meredith E. Pittman'', Ralph H. Hruban4, Bert Vogelstein“ & Martin A. NowaIc2-1.6
Most cancers in humans are large, measuring centimetres in We first
https://www.justice.gov/epstein/files/DataSet%209/EFTA00603737.pdf